Kiora Pharmaceuticals Files 8-K
Ticker: KPHMW · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, company-update
Related Tickers: KPRX
TL;DR
Kiora Pharma filed an 8-K, but it's light on details.
AI Summary
Kiora Pharmaceuticals, Inc. filed an 8-K on July 30, 2024, reporting other events and financial statements. The company, formerly known as Eyegate Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Encinitas, CA. The filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This filing indicates Kiora Pharmaceuticals is making a regulatory submission, but lacks specific details on the nature of the events or financial updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K with no immediate negative or positive financial disclosures.
Key Players & Entities
- KIORA PHARMACEUTICALS, INC. (company) — Registrant
- EYEGATE PHARMACEUTICALS INC (company) — Former company name
- July 30, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Encinitas, CA (location) — Business address
FAQ
What specific 'Other Events' are being reported by Kiora Pharmaceuticals?
The provided text does not specify the nature of the 'Other Events' reported in the 8-K filing.
Are there any financial statements included in this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific content or figures are not detailed in the provided text.
When was Kiora Pharmaceuticals, Inc. formerly known as Eyegate Pharmaceuticals Inc.?
The date of the name change from Eyegate Pharmaceuticals Inc. to Kiora Pharmaceuticals, Inc. is not explicitly stated in the provided text, only that it was a former name.
What is the primary business of Kiora Pharmaceuticals, Inc.?
Kiora Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
What is the physical address of Kiora Pharmaceuticals, Inc.?
The company's business address is 332 Encinitas Blvd., Suite 102, Encinitas, CA 92024.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-07-30 07:02:02
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
Filing Documents
- kprx-20240730.htm (8-K) — 24KB
- exhibit991-pressreleaseema.htm (EX-99.1) — 13KB
- 0001372514-24-000099.txt ( ) — 165KB
- kprx-20240730.xsd (EX-101.SCH) — 2KB
- kprx-20240730_lab.xml (EX-101.LAB) — 22KB
- kprx-20240730_pre.xml (EX-101.PRE) — 13KB
- kprx-20240730_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On July 30, 2024, Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has received European Orphan Medicinal Product Designation for KIO-301 for the treatment of inherited retinal dystrophies. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharmaceuticals, Inc. dated July 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Executive Vice President and Chief Financial Officer (Principal financial and accounting officer) Date: July 30, 2024